We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.
- Authors
Blumenschein, George R, Jr; Paulus, Rebecca; Curran, Walter J; Robert, Francisco; Fossella, Frank; Werner-Wasik, Maria; Herbst, Roy S; Doescher, Philip O; Choy, Hak; Komaki, Ritsuko
- Abstract
Non-small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical models, it demonstrates radiosensitization properties. We report a phase II trial testing the combination of cetuximab with chemoradiotherapy (CRT) in unresectable stage III NSCLC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 17, p2312
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.31.7875